Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 27

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

Blood (2023) 142 (Supplement 1): 3099.

https://doi.org/10.1182/blood-2023-179061

Published: 2023

Journal Articles

PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

Haihui Lu, Adwait Oka, Michelle Coulson, Joseph Ryan Polli, Kimberly Aardalen, Melissa Ramones, Dana B Walker, Ana Carrion, Dylan Alexander, Matthieu Klopfenstein, Masaki Akiyama, Francesca Rucci, Brian Granda, Alessandro Pastore

Blood (2022) 140 (Supplement 1): 3148.

https://doi.org/10.1182/blood-2022-168904

Published: 2022

Journal Articles

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Farhad Ravandi, MBBS, Asad Bashey, MD PhD, Wendy Stock, MD, James M. Foran, MD, Raya Mawad, MD, Daniel Egan, MD, William Blum, MD, Allen Yang, MD PhD, Alessandro Pastore, MD, Chelsea Johnson, BSN,RN, Shuo Zheng, Musa Yilmaz, MD, Alice S. Mims, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-134746

Published: 2020

Journal Articles

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

Blood (2019) 134 (Supplement_1): 657.

https://doi.org/10.1182/blood-2019-122663

Published: 2019

Journal Articles

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Blood (2019) 134 (Supplement_1): 473.

https://doi.org/10.1182/blood-2019-127122

Published: 2019

Journal Articles

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

Sydney X. Lu, MD PhD, Eric Wang, Alessandro Pastore, Chen Xufeng, PhD, Jochen Imig, PhD, Stanley C Lee, PhD, Yohana Ghebrechristos, Akihide Yoshimi, MD, Lillian E Bitner, BSc, Michelle Ki, BSc, Andreas Kloetgen, Kuan-Ting Lin, PhD, Raoul Tibes, MD PhD, Adrian R. Krainer, PhD, Taisuke Uehara, Takashi Owa, PhD, Iannis Aifantis, PhD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 427.

https://doi.org/10.1182/blood-2018-99-111430

Published: 2018

Journal Articles

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

Blood (2018) 132 (Supplement 1): 4096.

https://doi.org/10.1182/blood-2018-99-118000

Published: 2018

Journal Articles

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Anna S Nam, MD, Kyu-Tae Kim, PhD, Ronan Chaligne, PhD, Franco Izzo, PhD, Chelston Ang, MS, Nathaniel Omans, MS, Alessandro Pastore, Justin Taylor, MD, Alicia Alonso, Wayne Tam, MD PhD, Ronald Hoffman, MD, Joseph Scandura, MDPhD, Raul Rabadan, PhD, Omar I Abdel-Wahab, MD, Peter Smibert, PhD, Dan A. Landau, MD PhD

Blood (2018) 132 (Supplement 1): 541.

https://doi.org/10.1182/blood-2018-99-119236

Published: 2018

Journal Articles

Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L

Anagha Deshpande, PhD, Benson Chen, Parham Ramezani-Rad, PhD, Alessandro Pastore, Luyi Zhao, M.S., Oliver Weigert, MD, Scott A. Armstrong, MD PhD, Robert C Rickert, PhD, Bing Ren, Aniruddha J. Deshpande, PhD

Blood (2018) 132 (Supplement 1): 2839.

https://doi.org/10.1182/blood-2018-99-115475

Published: 2018

Journal Articles

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Benjamin H Durham, MD BS, Estibaliz Lopez-Rodrigo, MD, David H Abramson, MD, Jennifer Picarsic, MD, Alessandro Pastore, Diana Mandelker, MD PhD, Michael Francis Walsh, MD, Maria E Arcila, MD, Marc Ladanyi, MD, David Solit, MD, Michael F. Berger, PhD, David M. Hyman, MD, Michelle Ki, BSc, Ira Dunkel, MD, Frederic Geissmann, MD PhD, Eli L Diamond, MD, Omar I Abdel-Wahab, MD

Blood (2018) 132 (Supplement 1): 49.

https://doi.org/10.1182/blood-2018-99-114248

Published: 2018

Journal Articles

Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution

Ronan Chaligne, PhD, Federico Gaiti, PhD, Franco Izzo, PhD, Steven Kothen-Hill, MS, Hongcang Gu, Kevin Huang, BS, Davide Risso, PhD, Rafael Schulman, BS, Ryan M Brand, Stanley C Lee, PhD, Asaf Poran, Kye-Tae Kim, PhD, Alessandro Pastore, Alicia Alonso, Andreas Gnirke, Catherine J. Wu, MD, Omar I Abdel-Wahab, MD, Alexander Meissner, PhD, Dan A. Landau, MD PhD

Blood (2018) 132 (Supplement 1): 1312.

https://doi.org/10.1182/blood-2018-99-115596

Published: 2018

Journal Articles

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

Blood (2018) 132 (16): 1695–1702.

https://doi.org/10.1182/blood-2018-03-837252

Published: 2018

Includes: Supplemental data

Journal Articles

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

Blood (2017) 130 (Supplement 1): 473.

https://doi.org/10.1182/blood.V130.Suppl_1.473.473

Published: 2017

Journal Articles

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Johannes Hellmuth, MD, Abner Louissaint, MD PhD, Monika Szczepanowski, PhD, Sarah Häbe, MD, Alessandro Pastore, MD, Annette M. Staiger, PhD, Sylvia Hartmann, Robert Kridel, Matthew D. Ducar, MS, Peter Koch, MD, Martin Dreyling, MD PhD, Martin-Leo Hansmann, MD, German Ott, MD, Andreas Rosenwald, MD, Randy D. Gascoyne, MD, David M. Weinstock, MD, Wolfgang Hiddemann, MD PhD, Wolfram Klapper, MD, Oliver Weigert, MD

Blood (2017) 130 (Supplement 1): 2735.

https://doi.org/10.1182/blood.V130.Suppl_1.2735.2735

Published: 2017

Journal Articles

Integrative Epigenomics Reveals Novel Chronic Lymphocytic Leukemia-Specific Chromatin States Associated with Epigenetic and Transcriptional Heterogeneity

Alessandro Pastore, MD, Federico Gaiti, PhD, Sydney X. Lu, MDPhD, Omar Abdel-Wahab, MD, Dan A. Landau, MD

Blood (2017) 130 (Supplement 1): 1723.

https://doi.org/10.1182/blood.V130.Suppl_1.1723.1723

Published: 2017

Journal Articles

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

Christian Grommes, MD, Alessandro Pastore, MD, Igor Gavrilovic, MD, Thomas Kaley, MD, Craig Nolan, MD, Antonio M. Omuro, MD, Julia Wolfe, Elena Pentsova, MD, Vaois Hatzoglou, MD, Ingo Mellinghoff, MD, Lisa DeAngelis, MD

Blood (2016) 128 (22): 783.

https://doi.org/10.1182/blood.V128.22.783.783

Published: 2016

Journal Articles

STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23

Michael W Bösl, Elisa Osterode, Deepak Bararia, PhD, Alessandro Pastore, MD, Anette M Staiger, German Ott, MD, Monika Szczepanowski, PhD, Wolfram Klapper, MD, Andreas Rosenwald, MD, Wolfgang Hiddemann, MD, Oliver Weigert, MD

Blood (2015) 126 (23): 3923.

https://doi.org/10.1182/blood.V126.23.3923.3923

Published: 2015

Journal Articles

Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy

Deepak Bararia, PhD, Michael Heide, Robert S. Welner, PhD, Tatiana Romashova, Alessandro Pastore, MD, Radhika Mathur, Randy D. Gascoyne, Robert Kridel, MD MPH, Boris G. Willson, PhD, Charles W.M. Roberts, MD PhD, Wolfgang Hiddemann, MD PhD, David M Weinstock, MD, Oliver Weigert, MD

Blood (2015) 126 (23): 571.

https://doi.org/10.1182/blood.V126.23.571.571

Published: 2015

Journal Articles

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Jean-Baptiste Micol, MD, Nicolas Duployez, Alessandro Pastore, MD, Robert Williams, Eunhee Kim, PhD, Stanley Lee, Benjamin Durham, MD PhD, Young Rock Chung, MS, Hana Cho, Claude Preudhomme, Omar Abdel-Wahab

Blood (2015) 126 (23): 302.

https://doi.org/10.1182/blood.V126.23.302.302

Published: 2015

Journal Articles

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Simone Ferrero, Alessandro Pastore, Roswitha Forstpointner, M.D., Christian W. Scholz, Antonio Pezzutto, Lothar Bergmann, Lorenz Truemper, Juergen Finke, Ulrich Keller, Marco Ladetto, Wolfgang Hiddemann, M.D., Oliver Weigert, Michael Unterhalt, Martin Dreyling

Blood (2013) 122 (21): 4384.

https://doi.org/10.1182/blood.V122.21.4384.4384

Published: 2013

NARROW

A Phase 1 Study of PIT565, a First-in-Class, Anti-CD3, Anti-CD19, Anti-CD2 Trispecific Antibody in Patients with Relapsed and/or Refractory B-Cell Malignancies

PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study

Aberrant Cathepsin S Induces a Supportive Immune Microenvironment in Follicular Lymphoma

PRMT5 Inhibition Modulates E2F1 Methylation and Gene Regulatory Networks Leading to Therapeutic Efficacy in JAK2VF Mutant MPN

Therapeutic Targeting of an RNA Splicing Factor Network for the Treatment of Myeloid Neoplasms

Clinicogenetic Risk Models in Patients Randomized to Receive Consolidative Autologous Stem-Cell Transplantation after Frontline R-CHOP for Advanced Follicular Lymphoma: An Analysis from the GLSG2000 Trial

High Throughput Droplet Single-Cell Genotyping of Transcriptomes (GoT) Reveals the Cell Identity Dependency of the Transcriptional Output of Somatic Mutations

Targeting MYC-Driven B-Cell Lymphoma By Inhibition of the Histone Methyltransferase DOT1L

Activating Mutations in CSF1R and Additional Receptor Tyrosine Kinases in Sporadic and Familial Histiocytic Neoplasms

Multimodal Single-Cell Profiling Defines the Epigenetic Determinants of Chronic Lymphocytic Leukemia Evolution

Duodenal-type and nodal follicular lymphomas differ by their immune microenvironment rather than their mutation profiles

Spliceosomal Dysfunction Is a Critical Mediator of IDH2 Mutant Leukemogenesis

The Mutational Landscape and Immune Microenvironment of Primary Intestinal Follicular Lymphoma (PIFL)

Integrative Epigenomics Reveals Novel Chronic Lymphocytic Leukemia-Specific Chromatin States Associated with Epigenetic and Transcriptional Heterogeneity

Single-Agent Ibrutinib in Recurrent/Refractory Central Nervous System Lymphoma

STAT6 Is Recurrently and Significantly Mutated in Follicular Lymphoma and Enhances the IL-4 Induced Expression of Membrane-Bound and Soluble CD23

Disruptive ARID1A Mutations in Follicular Lymphoma Impair DNA Repair Efficiency and Are Associated with Favorable Outcome in Patients Receiving First-Line Immunochemotherapy

ASXL2 Is a Novel Mediator of RUNX1-ETO Transcriptional Function and Collaborates with RUNX1-ETO to Promote Leukemogenesis

Radioimmunotherapy In Relapsed/Refractory Mantle Cell Lymphoma Patients: Final Results Of a European MCL Network Phase II Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only